March 25, 2024
Press Release

Brain Trust Bio Receives Approval for Patient Trials Targeting ALS and other CNS Diseases with Continuous Intrathecal Drug Delivery Method

The approval sets the stage for patient trials in Australia designed to enhance treatment efficacy and patient outcomes in the battle against debilitating neurological conditions, and would enable a direct progression to Phase II trials in the U.S. without repetition. ATLANTA, March 25, 2022 – Brain Trust Bio (BTB), a leader in the development of […]

» Read more
August 1, 2022
Press Release

Brain Trust Bio Enters Investigational New Drug Enabled Studies for Continuous Intrathecal Drug Delivery Method

ATLANTA, August 1, 2022 — Brain Trust Bio , a next-generation biotechnology company, dedicated to improving the performance of the best medicines for central nervous system (CNS) conditions, today announced it has entered into Investigational New Drug (IND)-enabled studies for its continuous intrathecal (IT) drug delivery method. “The acceptance of our application to enter into […]

» Read more